HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS.

Abstract
Eighty-one women with psychosis of schizophrenic and paranoid type were assigned to a double-blind study comparing the clinical effects of melperone (100 mg X 3) and thiothixene (10 mg X 3). The antipsychotic effect was evaluated by clinical rating according to the CPRS and the NOSIE-30 scales before and after 2 and 4 weeks of drug treatment. A satisfactory interrater reliability was obtained for the CPRS. Significant correlation was also found between the CPRS and NOSIE ratings. Treatment with both drugs was associated with significant reductions in morbidity as estimated by several measures of therapeutic effect from the CPRS, by the NOSIE scale and by global ratings. There were no marked differences at any rating time point between the drugs in this regard. There were more extrapyramidal side effects in the thiothixene group than in the melperone-treated patients. The results encourage the use and further evaluation of melpherone in the treatment of psychotic patients.
AuthorsL Bjerkenstedt, C Härnryd, V Grimm, B Gullberg, G Sedvall
JournalArchiv fur Psychiatrie und Nervenkrankheiten (Arch Psychiatr Nervenkr (1970)) Vol. 226 Issue 3 Pg. 157-72 (Dec 14 1978) Germany
PMID32861 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Antipsychotic Agents
  • Thiothixene
Topics
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Female
  • Humans
  • Psychiatric Status Rating Scales
  • Schizophrenia (drug therapy)
  • Thiothixene (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: